The price of the first domestic anti -new crown oral medication was initially set for no more than 300 yuan per bottle

Guangzhou Daily News (All Media Reporter Tu Duanyu) On August 7, Henan Real Biotechnology Co., Ltd. reported that at present, the price of Azf, which treats the new crown pneumonia, is initially set. 35 bottles, 1mg per piece. On July 25, in accordance with the relevant provisions of the Drug Management Law, the State Drug Administration shall conduct emergency review and approval in accordance with the special approval procedures for the drug, and approve the conditions of Henan Real Biotechnology Co., Ltd. Azf fixed tablet. Application. This means that Azf's fixed film has become the first newly -developed oral small crown therapy drug in China.

It is worth noting that as of the end of June this year, only two new crown small molecular drugs in the world were approved for listing. One is Molnupiravir (Monpiravir) in Merck, and the other is Paxlovid of Pfizer. Among them, PAXLOVID was approved by the China State Drug Administration in February this year. At present, the latter's domestic price is 2300 yuan/box/treatment.

It is reported that shortly after the application of Azf's fixed setting, the real creature submitted a listing application to the Hong Kong Stock Exchange. The prospectus shows that the real creature has hired independent third -party Beijing Union production of Azfdin. For the commercialization of Azfdin, it has entered into a strategic agreement with several leading pharmaceutical manufacturers (including Beijing Union) in China. At the same time, the real creature pointed out that it has a self -production capacity of 22,262 square meters of a total construction area, with an annual production capacity of about 1 billion tablets Azfdin, and plans to seek to include Azf into the Chinese national medical insurance directory.

- END -